- Home
- EML vs KLTOW Comparison
EML vs KLTOW Comparison
Compare EML & KLTOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EML | KLTOW |
|---|---|---|
| Founded | 1858 | N/A |
| Country | United States | United States |
| Employees | N/A | 3 |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.2M | N/A |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | EML | KLTOW |
|---|---|---|
| Price | $20.23 | $0.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 10.5K | N/A |
| Earning Date | 11-04-2025 | N/A |
| Dividend Yield | ★ 2.18% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $258,121,226.00 | N/A |
| Revenue This Year | $1.56 | N/A |
| Revenue Next Year | $7.00 | N/A |
| P/E Ratio | $19.53 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $18.49 | N/A |
| 52 Week High | $30.72 | N/A |
Technical Indicators
Market Signals| Indicator | EML | KLTOW |
|---|---|---|
| Relative Strength Index (RSI) | 54.28 | 51.86 |
| Support Level | $19.73 | $0.13 |
| Resistance Level | $20.86 | $0.15 |
| Average True Range (ATR) | 0.60 | 0.02 |
| MACD | 0.22 | 0.00 |
| Stochastic Oscillator | 79.67 | 50.71 |
Price Performance
Historical ComparisonAbout EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About KLTOW Klotho Neurosciences Inc. Warrant
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.